Payment overview · 2025
General Payments
$224.78
11 reported records · 5 companies
Healthcare provider profile · identity verified
Jon E Dornacker, MD
Allopathic & Osteopathic Physicians|Family Medicine · GARRISON, ND · NPI 1801804588
Verified facts
What the public records show
CMS Open Payments records show Jon E Dornacker, MD received $224.78 in general payments during 2025 across 11 reported records.
ABBVIE INC. accounted for 39.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Synthroid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 195 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $89.26 | 39.7% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $55.72 | 24.8% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $36.33 | 16.2% | 2 | 2025 |
| Ionis Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $25.00 | 11.1% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $18.47 | 8.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $199.78 | 10 |
| Education | $25.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $89.26 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $89.26 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $40.39 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $36.33 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $29.66 | 2 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $18.47 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $16.62 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
195 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 754 | 97 |
| Furosemide | Furosemide | 721 | 80 |
| Amlodipine Besylate | Amlodipine Besylate | 664 | 89 |
| Potassium Chloride | Potassium Chloride | 590 | 64 |
| Atorvastatin Calcium | Atorvastatin Calcium | 481 | 68 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 414 | 69 |
| Sertraline Hcl | Sertraline Hcl | 328 | 36 |
| Fenofibrate | Fenofibrate | 318 | 41 |
| Losartan Potassium | Losartan Potassium | 299 | 34 |
| Pantoprazole Sodium | Pantoprazole Sodium | 256 | 34 |
| Irbesartan | Irbesartan | 221 | 41 |
| Metoprolol Succinate | Metoprolol Succinate | 214 | 42 |
| Omeprazole | Omeprazole | 202 | 25 |
| Jardiance | Empagliflozin | 195 | 23 |
| Quetiapine Fumarate | Quetiapine Fumarate | 188 | suppressed |
| Simvastatin | Simvastatin | 178 | 13 |
| Eliquis | Apixaban | 177 | 19 |
| Lisinopril | Lisinopril | 174 | 39 |
| Carvedilol | Carvedilol | 173 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 170 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 169 | 20 |
| Tamsulosin Hcl | Tamsulosin Hcl | 163 | 28 |
| Pravastatin Sodium | Pravastatin Sodium | 154 | 15 |
| Hydrochlorothiazide | Hydrochlorothiazide | 153 | 26 |
| Metformin Hcl Er | Metformin Hcl | 149 | 32 |
| Metformin Hcl | Metformin Hcl | 147 | 26 |
| Metoprolol Tartrate | Metoprolol Tartrate | 146 | 16 |
| Memantine Hcl | Memantine Hcl | 137 | suppressed |
| Mirtazapine | Mirtazapine | 134 | suppressed |
| Gabapentin | Gabapentin | 133 | 26 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 129 | 13 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 123 | 44 |
| Allopurinol | Allopurinol | 122 | 17 |
| Xarelto | Rivaroxaban | 122 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 109 | 12 |
| Donepezil Hcl | Donepezil Hcl | 108 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 95 | 16 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 93 | 21 |
| Spironolactone | Spironolactone | 93 | 14 |
| Nystatin | Nystatin | 91 | 19 |
| Glimepiride | Glimepiride | 85 | 19 |
| Celecoxib | Celecoxib | 82 | 15 |
| Bupropion Xl | Bupropion Hcl | 81 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 81 | suppressed |
| Baclofen | Baclofen | 80 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 75 | suppressed |
| Atenolol | Atenolol | 73 | 15 |
| Clonazepam | Clonazepam | 72 | suppressed |
| Ondansetron Odt | Ondansetron | 72 | 36 |
| Citalopram Hbr | Citalopram Hydrobromide | 71 | suppressed |
| Famotidine | Famotidine | 71 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 69 | 16 |
| Montelukast Sodium | Montelukast Sodium | 62 | 11 |
| Novolog Flexpen | Insulin Aspart | 62 | 13 |
| Pregabalin | Pregabalin | 62 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 62 | suppressed |
| Aripiprazole | Aripiprazole | 61 | suppressed |
| Lorazepam | Lorazepam | 61 | 15 |
| Latanoprost | Latanoprost | 57 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 55 | 12 |
| Prednisone | Prednisone | 54 | 27 |
| Ropinirole Hcl | Ropinirole Hcl | 54 | suppressed |
| Easy Touch Safety Pen Needle | Pen Needle, Diabetic, Safety | 53 | suppressed |
| Tradjenta | Linagliptin | 52 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 51 | 39 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 51 | 44 |
| Divalproex Sodium | Divalproex Sodium | 51 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 51 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 50 | 13 |
| Vascepa | Icosapent Ethyl | 50 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 49 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 47 | suppressed |
| Myrbetriq | Mirabegron | 47 | suppressed |
| Risperidone | Risperidone | 47 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 45 | suppressed |
| Chlorthalidone | Chlorthalidone | 44 | 14 |
| Meloxicam | Meloxicam | 44 | suppressed |
| Bumetanide | Bumetanide | 42 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 42 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 41 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 41 | suppressed |
| Fluconazole | Fluconazole | 41 | 21 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 39 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 35 | suppressed |
| Carbamazepine | Carbamazepine | 35 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 35 | suppressed |
| Ozempic | Semaglutide | 35 | suppressed |
| Trulicity | Dulaglutide | 35 | suppressed |
| Rexulti | Brexpiprazole | 34 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 34 | 15 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 33 | 28 |
| Divalproex Sodium Er | Divalproex Sodium | 33 | suppressed |
| Levofloxacin | Levofloxacin | 33 | 27 |
| Potassium Citrate Er | Potassium Citrate | 33 | suppressed |
| Telmisartan | Telmisartan | 33 | suppressed |
| Alprazolam | Alprazolam | 32 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 32 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 32 | suppressed |
| Synthroid | Levothyroxine Sodium | 32 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 31 | suppressed |
| Ezetimibe | Ezetimibe | 31 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 31 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 30 | suppressed |
| Fentanyl | Fentanyl | 29 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 29 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 29 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 28 | suppressed |
| Dexamethasone | Dexamethasone | 27 | 27 |
| Oxybutynin Chloride | Oxybutynin Chloride | 27 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 27 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 27 | 16 |
| Bupropion Hcl Sr | Bupropion Hcl | 26 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 26 | suppressed |
| Finasteride | Finasteride | 26 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 26 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 26 | suppressed |
| Anastrozole | Anastrozole | 25 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 25 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 24 | suppressed |
| Scopolamine | Scopolamine | 24 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 24 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 23 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 23 | 12 |
| Meclizine Hcl | Meclizine Hcl | 22 | suppressed |
| Levetiracetam | Levetiracetam | 21 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 20 | suppressed |
| Ketoconazole | Ketoconazole | 20 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 20 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 19 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 19 | suppressed |
| Amoxicillin | Amoxicillin | 18 | 13 |
| Hydrocortisone | Hydrocortisone | 18 | suppressed |
| Cephalexin | Cephalexin | 17 | 15 |
| Minocycline Hcl | Minocycline Hcl | 17 | suppressed |
| Novofine Autocover | Pen Needle, Diabetic, Safety | 17 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 16 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 16 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 16 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 16 | suppressed |
| Restasis Multidose | Cyclosporine | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 15 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 15 | suppressed |
| Mounjaro | Tirzepatide | 15 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Calcitriol | Calcitriol | 14 | suppressed |
| Diazepam | Diazepam | 14 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 14 | suppressed |
| Roflumilast | Roflumilast | 14 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Timolol Maleate | Timolol Maleate | 13 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 12 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | 11 |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 11 | suppressed |
| Loperamide | Loperamide Hcl | 11 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 11 | suppressed |
| Metolazone | Metolazone | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $224.78 · 11 records | ABBVIE INC. | EVENITY, MOUNJARO, PROLIA, QULIPTA, TRINTELLIX, UBRELVY, ZEPBOUND | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error